| The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand. | |
| | |
MedLine Citation:
|
PMID: 19744294 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To identify differences in the range of medicines available and subsidized for ambulatory care in Finland and New Zealand. METHODS: Medical entities listed in national product information sources and their subsidy statuses were compared. The number and overlap of entities available and subsidized were determined. Differences in the age of subsidized medicines were compared using the date of first registration. Differences in licensing delays were compared using a selection of new innovative medicines that provide health gain. RESULTS: Within the inclusion criteria, 779/763 entities were available and 495/471 subsidized in Finland/New Zealand, of which around 30% (30.9% Finland, 29.5% New Zealand) were not available and approximately 40% (41.4% Finland, 38.4% New Zealand) not subsidized in the other country. The proportion of fully subsidized entities was higher in New Zealand (86.2%/29.1%). The entities only subsidized in New Zealand were significantly older than those only subsidized in Finland and the share of licensed and launched innovative medicines was significantly smaller in New Zealand. The differences were equally distributed across the therapeutic groups but clinically relevant differences were rarely found. CONCLUSIONS: In New Zealand, medicines are heavily subsidized across therapy groups, but those uniquely subsidized were older entities. In Finland, more "newer" medicines are subsidized and available, but the level and coverage of subsidy is lower and thus, the patient cost burden is higher. The cost containment policies adopted seem to affect patients' access to medicines mainly by availability in New Zealand and by affordability in Finland. |
| | |
Authors:
|
Katri Aaltonen; Rajan Ragupathy; June Tordoff; David Reith; Pauline Norris |
Related Documents
:
|
1604434 - Does the philosophy of medicine exist? 20224944 - Superior efficacy of new medicines? 20602344 - Linking a pharmaceutical claims database with a birth defects registry to investigate b... 21391834 - Antimutagenic activity of two medicinal phytoextracts in somatic cells of drosophila me... 17356504 - Medical simulation in anesthesiology training. 16303444 - Videokeratoscopy in contact lens practice. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2009-09-10 |
Journal Detail:
|
Title: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Volume: 13 ISSN: 1524-4733 ISO Abbreviation: Value Health Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-07-29 Completed Date: 2010-09-08 Revised Date: 2010-11-22 |
Medline Journal Info:
|
Nlm Unique ID: 100883818 Medline TA: Value Health Country: United States |
Other Details:
|
Languages: eng Pagination: 148-56 Citation Subset: IM |
Affiliation:
|
School of Pharmacy, University of Otago, New Zealand. katri.aaltonen@uku.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost Control
/
methods Cross-Cultural Comparison Drug Utilization / economics Economics, Pharmaceutical* Financing, Government Finland Health Policy / economics* Health Services Accessibility / economics* Humans New Zealand Pharmaceutical Preparations / economics*, supply & distribution Pharmacopoeias as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Pharmaceutical Preparations |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patient characteristics impacting health state index scores, measured by the EQ-5D of females with s...
Next Document: Understanding the medical and nonmedical value of diagnostic testing.